Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Phase 2 Completed 19 enrolled National Cancer Institute (NCI)

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory diffuse or mediastinal large B-cell lymphoma. Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

Timeline

Start: 2007-02
Primary completion: 2012-01
Completion: 2012-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	—	Oral

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Summary

Timeline

Drugs

Indications